Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Lipids enter brain mapping limelight
Two new studies, including the first whole-brain lipid atlas in mice, uncover unforeseen complexity and influence during pregnancy and aging.
Lipids enter brain mapping limelight
Two new studies, including the first whole-brain lipid atlas in mice, uncover unforeseen complexity and influence during pregnancy and aging.
Behavioral phenomics in zebrafish; and more
Here is a roundup of autism-related news and research spotted around the web for the week of 26 October.
Behavioral phenomics in zebrafish; and more
Here is a roundup of autism-related news and research spotted around the web for the week of 26 October.
Neuroscience gave AI its start. What happens now?
David Sussillo maps the two fields' divergent paths, and where they might still meet.
Neuroscience gave AI its start. What happens now?
David Sussillo maps the two fields' divergent paths, and where they might still meet.